TY - JOUR AU - Bartos, Csilla AU - Révész, Piroska AU - Horváth, Tamás AU - Varga, Patrícia Orsolya AU - Ambrus, Rita TI - Comparison of Modern In Vitro Permeability Methods with the Aim of Investigation Nasal Dosage Forms JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 13 PY - 2021 IS - 6 PG - 12 SN - 1999-4923 DO - 10.3390/pharmaceutics13060846 UR - https://m2.mtmt.hu/api/publication/32085404 ID - 32085404 LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Tamás AU - Ambrus, Rita AU - Völgyi, Gergely AU - Budai-Szűcs, Mária AU - Márki, Árpád AU - Sipos, Péter AU - Bartos, Csilla AU - Seres, Adrienn AU - Sztojkov-Ivanov, Anita AU - Takácsné Novák, Krisztina AU - Csányi, Erzsébet AU - Gáspár, Róbert AU - Révész, Piroska TI - Effect of solubility enhancement on nasal absorption of meloxicam JF - EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES J2 - EUR J PHARM SCI VL - 95 PY - 2016 SP - 96 EP - 102 PG - 7 SN - 0928-0987 DO - 10.1016/j.ejps.2016.05.031 UR - https://m2.mtmt.hu/api/publication/3076538 ID - 3076538 N1 - \n Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary \n Goodwill Pharma Ltd., Szeged, Hungary \n Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary \n Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary \n Cited By :3 \n Export Date: 20 November 2018 \n CODEN: EPSCE \n Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, University of Szeged, Eötvös u. 6, Hungary Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary Goodwill Pharma Ltd., Szeged, Hungary Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary Cited By :11 Export Date: 2 February 2021 CODEN: EPSCE Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, Eötvös u. 6, Hungary Chemicals/CAS: meloxicam, 71125-38-7; Anti-Inflammatory Agents, Non-Steroidal; meloxicam; Thiazines; Thiazoles Manufacturers: Egis, Hungary Department of Pharmaceutical Technology, University of Szeged, Szeged, Hungary Goodwill Pharma Ltd., Szeged, Hungary Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary Department of Pharmaceutical Chemistry, Semmelweis University, Budapest, Hungary Cited By :12 Export Date: 1 June 2021 CODEN: EPSCE Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, Eötvös u. 6, Hungary Chemicals/CAS: meloxicam, 71125-38-7; Anti-Inflammatory Agents, Non-Steroidal; meloxicam; Thiazines; Thiazoles Manufacturers: Egis, Hungary AB - Besides the opioids the standard management of the World Health Organization suggests NSAIDs (non-steroidal anti-inflammatory drugs) alone or in combination to enhance analgesia in malignant and non-malignant pain therapy. The applicability of NSAIDs in a nasal formulation is a new approach in pharmaceutical technology. In order to enhance the nasal absorption of meloxicam (MX) as an NSAID, its salt form, meloxicam potassium monohydrate (MXP), registered by Egis Plc., was investigated in comparison with MX. The physico-chemical properties of the drugs (structural analysis, solubility and dissolution rate) and the mucoadhesivity of nasal formulations were controlled. In vitro and in vivo studies were carried out to determine the nasal applicability of MXP as a drug candidate in pain therapy. It can be concluded that MX and MXP demonstrated the same equilibrium solubility at the pH5.60 of the nasal mucosa (0.017mg/ml); nonetheless, MXP indicated faster dissolution and a higher permeability through the synthetic membrane. The animal studies justified the short Tmax value (15min) and the high AUC of MXP, which is important in acute pain therapy. It can be assumed that the low mucoadhesivity of MXP spray did not increase the residence time in the nasal cavity, and the elimination from the nasal mucosa was therefore faster than in the case of MX. Further experiments are necessary to prove the therapeutic relevance of this MXP-containing innovative intranasal formulation. LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Tamás AU - Bartos, Csilla AU - Bocsik, Alexandra AU - Kiss, Lóránd AU - Veszelka, Szilvia AU - Deli, Mária Anna AU - Újhelyi, G AU - Révész, Piroska AU - Ambrus, Rita TI - Cytotoxicity of different excipients on RPMI 2650 human nasal epithelial cells JF - MOLECULES J2 - MOLECULES VL - 21 PY - 2016 IS - 5 PG - 5 SN - 1420-3049 DO - 10.3390/molecules21050658 UR - https://m2.mtmt.hu/api/publication/3066564 ID - 3066564 LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Tamás AU - Ambrus, Rita AU - Révész, Piroska TI - Nazális gyógyszerformák permeabilitási vizsgálata Side-Bi-Side™ horizontális cella alkalmazásával JF - ACTA PHARMACEUTICA HUNGARICA J2 - ACTA PHARM HUNG VL - 85 PY - 2015 IS - 1 SP - 19 EP - 28 PG - 10 SN - 0001-6659 UR - https://m2.mtmt.hu/api/publication/2920571 ID - 2920571 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Bartos, Csilla AU - Ambrus, Rita AU - Sipos, Péter AU - Budai-Szűcs, Mária AU - Csányi, Erzsébet AU - Gáspár, Róbert AU - Márki, Árpád AU - Seres, Adrienn AU - Sztojkov-Ivanov, Anita AU - Horváth, Tamás AU - Révész, Piroska TI - Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles JF - INTERNATIONAL JOURNAL OF PHARMACEUTICS J2 - INT J PHARM VL - 491 PY - 2015 IS - 1-2 SP - 198 EP - 207 PG - 10 SN - 0378-5173 DO - 10.1016/j.ijpharm.2015.06.046 UR - https://m2.mtmt.hu/api/publication/2917042 ID - 2917042 N1 - Department of Pharmaceutical Technology, Universi- Ty of Szeged H-6720 Szeged, University of Szeged, Eötvös u. 6, Szeged, Hungary Richter Gedeon Nyrt., Budapest, Hungary Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary Cited By :21 Export Date: 2 February 2021 CODEN: IJPHD Correspondence Address: Szabó-Révész, P.; Department of Pharmaceutical Technology, Eötvös u. 6, Hungary; email: revesz@pharm.u-szeged.hu Chemicals/CAS: hyaluronic acid, 31799-91-4, 9004-61-9, 9067-32-7; meloxicam, 71125-38-7; piroxicam, 36322-90-4; polyvinyl alcohol, 37380-95-3, 9002-89-5; Anti-Inflammatory Agents, Non-Steroidal; Excipients; Hyaluronic Acid; meloxicam; Membranes, Artificial; Polyvinyl Alcohol; Thiazines; Thiazoles LA - English DB - MTMT ER - TY - CONF AU - Bartos, Csilla AU - Révész, Piroska AU - Horváth, Tamás AU - Ambrus, Rita TI - Application of acoustic cavitation in order to prepare nasal formulation T2 - 10th Central European Symposium on Pharmaceutical Technology PY - 2014 SP - 75 EP - 76 PG - 2 UR - https://m2.mtmt.hu/api/publication/3083603 ID - 3083603 LA - English DB - MTMT ER - TY - JOUR AU - Horváth, Tamás AU - Bartos, Csilla AU - Révész, Piroska AU - Ambrus, Rita TI - Nazális gyógyszerformák hatóanyagának permeabilitás vizsgálata módosított horizontális cella alkalmazásával JF - GYÓGYSZERÉSZET J2 - GYÓGYSZERÉSZET VL - 58 PY - 2014 IS - S1 SP - S109 EP - S109 PG - 1 SN - 0017-6036 UR - https://m2.mtmt.hu/api/publication/2597098 ID - 2597098 N1 - „A kutatás a TÁMOP 4.2.4.A/2-11-1-2012-0001 azonosító számú Nemzeti Kiválóság Program – Hazai hallgatói, illetve kutatói személyi támogatást biztosító rendszer kidolgozása és működtetése konvergencia program című kiemelt projekt keretében zajlott. A projekt az Európai Unió támogatásával, az Európai Szociális Alap társfinanszírozásával valósul meg.” LA - Hungarian DB - MTMT ER -